{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"17.96","upperLimit":"17.96","value":"17.96"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"description":"Median overall survival for patients treated with immunotherapy and radiotherapy will be assessed. overall survival will be defined as the time from first treatment day until death. Overall survival will be assessed by Kaplan-Meier survival analysis and 95% confidence interval.","dispersionType":"95% Confidence Interval","groups":[{"description":"All eligible patients will receive immunotherapy (Nivolumab) plus radiotherapy (6 Gy x 5 fractions) to a targetable lesion.\n\n* Nivolumab 240 mg IV starts with the first radiotherapy fraction 240 mg IV every 2 weeks from first radiotherapy fraction until disease prograssion or dose limiting toxicity is reached\n* Radiotherapy Dose of 6 Gy x 5 days will be given (patients will receive 1 fraction over 5 days for a total of 5 fractions) during the first week of starting Nivolumab\n\nNivolumab 240mg: Patients with multiple myeloma will receive Nivolumab intravenously at 240 mg every two weeks. Infusions will be given over 60 minutes (not bolus or IV push). Patients will continue to receive infusions every two weeks until disease progression or dose limiting toxicity is reached.\n\nRadiation therapy: Patients will receive radiation for 5 consecutive days. A dose of 6 Gy x 5 days will be administered. Patients may receive radiotherapy to an additional site at 12 weeks if they have stable disease.","id":"OG000","title":"Nivolumab/Radiotherapy"}],"paramType":"MEDIAN","populationDescription":"All patients withdrew consent after progressing, so no follow up survival data was collected (with the exception of 1 patient who only allowed for survival follow up after being taken off study for progression).","reportingStatus":"POSTED","timeFrame":"through study completion","title":"To Determine the Median Overall Survival for Patients Treated With Immunotherapy and Radiotherapy Will be Assessed.","type":"SECONDARY","unitOfMeasure":"months"}